Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Evaluation of the living kidney donor Koller H; Mayer GNephrol Dial Transplant 2004[Jul]; 19 Suppl 4 (ä): iv41-4Living donor renal transplantation is the preferred treatment for end-stage renal failure as the risk-benefit ratio for the recipient usually very much favours this approach. However, the benefit for the donor is much harder to define and probably very small if pure medical criteria are considered. Nonetheless 'non-medical' issues (mostly socio-psychological) may outweigh the small medical risk. The medical pre-transplant evaluation of the potential donor must identify absolute contraindications and abnormalities, which would increase the peri-operative risk. Difficulties may arise, if during the process, minor abnormalities are detected that marginally increase the acute or especially the long-term risk or whose implications are not well defined. In this situation two options are available. If the transplant team assumes that donation per se is of no benefit for the donor, transplantation should not be performed. If, however, the supposed 'non-medical' benefit is large enough, this approach will be against the principle of 'doing no harm' because the individual is denied the possibility to help somebody and might suffer from the consequences. In these complicated cases the final decision should be with the potential donor after an intense discussion with everybody involved in the transplantation process. Such an approach, however, necessitates a post-donation follow-up programme to be offered.|*Kidney Transplantation/adverse effects/physiology[MESH]|*Living Donors[MESH]|*Nephrectomy[MESH]|Creatinine/metabolism[MESH]|Glomerular Filtration Rate[MESH]|Humans[MESH]|Kidney Failure, Chronic/epidemiology[MESH]|Male[MESH]|Middle Aged[MESH] |